Protocols

First Line Therapy

European MCL Network Trial (patients < 65 years)

Efficacy of 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and autologous stem cell transplantation versus alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation

» MCLyounger Trial

European MCL Network Trial (patients > 65 years)

Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs. R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation

» MCL elderly Trial

Relapsed Lymphoma

90Y-Radioimmunotherapy

Efficacy and safety of 90Y-Ibritumomab tiuxetan in patients with refractory or relapsed mantle cell lymphoma after/not appropriate for autologous stem cell transplantation

» 90Y-Ibritumomab Trial

Allogeneic Stem Cell Transplantation in Follicular and Mantle Cell Lymphoma

Prospective multicenter phase II study of the German Low Grade Lymphoma Study Group, the European MCL Network and the EBMT lymphoma working group: Allogeneic stem cell transplantation with dose reduced coditioning in patients with relapsed follicular and mantle cell lymphoma.

» Transplantation Trial